We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Clinical Chemistry Analyzer Processes 300 Tests per Hour

By Labmedica staff writers
Posted on 04 Aug 2008
A clinical chemistry analyzer has been launched for low- to medium-volume laboratories with throughput needs of up to 300 tests per hour.

Compact and reliable, the cobas c 311 analyzer is suitable for satellite, STAT, and smaller hospital laboratories. More...
It offers a comprehensive clinical chemistry menu of more than 100 assays. Up to 45 assays can be performed simultaneously. High onboard reagent stabilities and lot-to-lot calibration optimize reagent usage makes the analyzer cost-effective and convenient to use.

All reagents in the ergonomic cobas c packs are liquid and ready-to-use, and all components of a parameter are integrated into a single cassette. The integration of cobas e-services for electronic updates and downloads makes handling of application, calibrator, and control information seamless and precise. Special features of the 311 analyzer include intelligent clot detection, carryover-free ultrasonic mixing, and test-specific serum indices.

Introduced by Roche (Basel, Switzerland), the cobas c 311 analyzer represents the latest collaboration between the company and its strategic partner, Hitachi High Technologies (Tokyo, Japan). The analyzer was launched prior to the American Association of Clinical Chemistry (AACC) Congress, which was held on July 29-31, 3008, in Washington DC (USA). Dirk Ehlers, head of Roche professional diagnostics said, "The system will enable us to offer smaller laboratories many of the efficiencies and conveniences currently provided by the cobas 6000 analyzer series.”

The cobas c 311 analyzer complements the cobas 411 immunoanalyzer, which was released in December 2006. The two systems compose the cobas 4000 analyzer series, an efficient serum work-area solution designed to process more than 95% of the combined testing needs of low- to mid-volume laboratories.

Roche, a biotech company, is an innovator of products and services for the early detection, prevention, diagnosis, and treatment of diseases. Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders, and diseases of the central nervous system.


Related Links:
Roche
Hitachi High Technologies

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.